摘要
阿戈美拉汀是一种新型的抗抑郁药,为褪黑激素受体激动剂和5-羟色胺(5-HT)2C受体拮抗剂,目前处于Ⅲ期临床研究中。该药对重度抑郁症(MMD)疗效明显,不良反应小,能有效调整生物节律、改善睡眠质量,而无性功能障碍和撤药症状。本文对该药的研究进展作一综述。
Agomelatine as a new antidepressant drug with a potent agonist of melatonin receptors and an antagonist of the serotonin 5-HT2C receptor subtype is now being in late-phase trials for the treatment of major depressive disorder （MDD） as well as other antidepressants but with further more improvement of symptoms of depression and fewer adverse reactions. Agomelatine appears to have efficient effect on the circadian rhythm especially for improving sleep quality; without sexual dysfunction and discontinuation symptoms. The article provides an up-to-date review and progress of the agent.
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2009年第2期81-85,共5页
Chinese Journal of New Drugs and Clinical Remedies
关键词
抑郁症
抗抑郁药
受体
褪黑激素
阿戈美拉汀
depressive disorder
antidepressant drugs
receptors, melatonin
agomelatine
